TargetMol

Naldemedine

Product Code:
 
TAR-T33583
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33583-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33583-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33583-5mg5mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Naldemedine (S 297995) is a peripheral selective μ-opioid receptor antagonist being developed by Shionogi for the treatment of opioid-induced adverse reactions, including constipation, nausea, and vomiting. They are usually well tolerated, mainly with mild to moderate gastrointestinal side effects.
CAS:
916072-89-4
Formula:
C32H34N4O6
Molecular Weight:
570.646
Purity:
0.98
SMILES:
CC(C)(NC(=O)C1=C(O)[C@H]2Oc3c4c(C[C@H]5N(CC6CC6)CC[C@@]24[C@@]5(O)C1)ccc3O)c1nc(no1)-c1ccccc1

References

Migoya E, Fukumura K, Yamada T, Arjona Ferreira J. (426) Effect of naldemedine, a peripherally acting ?-opioid receptor antagonist, on QT interval. J Pain. 2016 Apr;17(4S):S81. doi: 10.1016/j.jpain.2016.01.403. PubMed PMID: 28162674. Kim AP, Baker DE. Daclizumab. Hosp Pharm. 2016 Dec;51(11):928-939. doi: 10.1310/hpj5111-928. PubMed PMID: 28057953; PubMed Central PMCID: PMC5199226. Webster L, Nagata T, Yamada T, Arjona Ferreira J. (479) A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction. J Pain. 2016 Apr;17(4S):S94. doi: 10.1016/j.jpain.2016.01.456. PubMed PMID: 28162732.